Patient
SITE013-0174
withdrawn Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE013 (USA) (Dr. Clarke)
consented 2026-04-07
Adverse events
5
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 5
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-04 (study day 89); relationship: not assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-12-21 (study day 75); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-18 (study day 72); relationship: NOT RELATED
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-23 (study day 47); relationship: NOT RELATED
Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-22 (study day 15); relationship: not assessed; serious criteria: life-threatening
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.